Rabaptin-5 beta (RABEP2)

Rabaptin-5 beta (RABEP2) is a regulatory protein involved primarily in membrane trafficking, endosomal fusion, and cilium assembly, functioning as a binding effector for Rab GTPases with a proposed—but likely limited—role in Rab5-dependent endocytosis[1][2][3]. RABEP2 acts as a substrate for glycogen synthase kinase-3 (GSK3), and its phosphorylation at Ser200 is a candidate biomarker of GSK3 activity[1][3]. Genetic studies implicate RABEP2 as a critical determinant in vascular remodeling and collateral vessel formation, influencing outcomes after ischemic stroke and modulating cerebrovascular integrity[1]. Proteomic studies show RABEP2 expression parallels tumorigenic progression in gastric cancer, indicating possible oncogenic involvement via dysregulation of Rab/Ras signaling pathways[1]. RABEP2 is not currently a direct drug target, but it is considered a promising candidate for therapeutic intervention and for biomarker applications, especially in the context of vascular and oncogenic disease[1][3].

Other names

Rab GTPase-binding effector protein 2Rabaptin-5betaRABPT5BFRAFLJ23282RABE2_HUMANRabaptin-5 beta

No drugs are currently documented to directly target RABEP2; phosphorylation status may be indirectly modulated by kinase inhibitors (e.g., GSK3 inhibitors)[3].